14 results about "SOX9" patented technology

The present application provides SOX9 inhibitor compounds and compositions and methods of use thereof. In certain aspects, the SOX9 inhibitor is a peptide comprising a portion of the SOX9 dimerization motif. In other aspects, the SOX9 inhibitor is a compound of the general formula Iwhere one A is H and the other is:and the remaining substituents are as defined in the application.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The present invention discloses the use of Avn Anthramides C (Avn C) as an inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the transcriptional activity state of SOX9, a key regulator of chondrogenesis. The disclosed invention shows significant improvements in mRNA gene expression (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

The invention discloses a cartilage cell targeting recombinant adeno-associated virus and a preparation method thereof, and belongs to the technical field of gene engineering. The recombinant adeno-associated virus is obtained by co-transfecting an HEK293 cell by using a recombinant plasmid pSSCMV-Cl2a1-SOX9 and a helper plasmid; and the recombinant plasmid pSSCMV-Cl2a1-SOX9 is obtained by inserting a fusion gene of Col2a1 and SOX9 into a pSSHG-CMV carrier. The preparation method comprises the following steps: step 1, constructing a recombinant plasmid pSSCMV-Col2a1-SOX9, and constructing the recombinant plasmid pSSCMV-Col2a1-SOX9; step 2, culturing the HEK293 cells, and waiting for transfection; and 3, co-transfecting the recombinant plasmid pSSCMV-Cl2a1-SOX9 obtained in the step 1, a pHelper plasmid and a pAAV-RC plasmid into the HEK293 cell cultured in the step 2, culturing, collecting a cell lysis solution, and carrying out iodixanol gradient centrifugation combined with Heparin chromatographic purification to obtain the recombinant adeno-associated virus. The recombinant adeno-associated virus obtained by the invention has targeting property and higher expression level.

Provided is a differentiation agent consisting essentially of SOX9 for generating oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided are methods of generating PSCs and methods of using PSCs to generate OPCs and oligodendrocytes.SOLUTION: A method comprising culturing pluripotent stem cells (PSCs) to produce a population of cells comprising oligodendrocyte progenitor cells (OPCs), wherein the PSCs express engineered nucleic acids encoding SOX9 at a level sufficient to differentiate the PSCs into OPCs in the absence of other transcription factors encoded by the engineered nucleic acids.SELECTED DRAWING: Figure 2C

This disclosure relates to the repair and / or regeneration of intervertebral discs in individuals that require it. To provide methods and compositions. [Solution] In a particular embodiment, for example, it is known that the intervertebral disc has degenerated tissue. Individuals who have, are suspected of having, or are at risk of having nucleus pulposus cells, nucleus pulposus-derived cells One or more components, a therapeutically effective amount of a conditioned medium produced from nucleus pulposus cells, are provided. In addition, fibroblasts, platelet-rich plasma (PRP), SOX9 (protein or nucleic acid) and / Alternatively, Tie2+ cells may be provided.

The invention discloses a pharmaceutical composition for inhibiting expression of leukemia tumor stem cell markers and application of the pharmaceutical composition, and relates to the technical field of leukocyte tumor cell inhibition. The active ingredients of the pharmaceutical composition are oleanolic acid and illlisemom. The invention reveals that oleanolic acid inhibits expression of key markers Sox9, Nanog, CD133 and CD44 of leukemia tumor stem cells by targeting FDX1 / DLAT axis for the first time, and further inhibits drug resistance and recurrence of malignant tumors. When the compound is used in combination with a copper ion carrier ilismor, a relatively large synergistic effect can be generated by inhibiting the expression of tumor stem cell markers Sox9, Nanog, CD133 and CD44, and the stemness of leukemia is remarkably inhibited. The composition provides a new drug development strategy with a clear mechanism for treatment of leukemia.

The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising (a) determining the level of SRY-box transcription factor 9 (SOX9) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the level of SOX9 determined in step a). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.

A method of differentiating nonhuman primate induced pluripotent stem cells (iPSCs) into astrocytes may include providing a modified vector comprising a piggyBac vector backbone configured to express SOX9 and NFIB. The piggyBac vector backbone may include terminal inverted repeats and transposase recognition sites that support stable genomic integration of the inserted differentiation factor genes. Introduction of the vector into nonhuman primate iPSCs, such as Macaca fascicularis iPSCs, may initiate transcriptional programs associated with astrocyte-lineage commitment and maturation. Expression of SOX9 and NFIB may facilitate the formation of astrocytic morphology and the development of molecular features associated with astrocytes, including process elaboration and lineage-specific marker expression. The method may further include culturing the transfected cells under conditions that support astrocytic differentiation and expansion, resulting in populations of astrocytes or induced astrocytes suitable for research, disease modeling, and / or therapeutic applications.

The invention provides a new medicine for treating gastric cancer, opens up a brand new application field of an alpha-glucosidase inhibitor, and provides a potential effective, safe and economical new treatment scheme for patients with gastric cancer; the invention also discloses a brand new anti-gastric cancer action mechanism of the alpha-glucosidase inhibitor, phosphorylation of PPP1CA at a T320 site is inhibited by down-regulating expression of a tumor inhibition factor RASAL2, and finally inactivation of a downstream p38 MAPK signal channel and a downstream Smad signal channel (a key medium of a TGF-beta channel) is caused. Expression of key genes related to tumor stem cell characteristics (LGR5, CD44 and SOX9), transcription factors (BACH1) and immune escape (PD-L1) is reduced through inhibition of the pathways, so that the effects of inhibiting proliferation of gastric cancer cells and reducing the malignancy degree of the gastric cancer cells are achieved.

The application relates to the field of biomedical technology, and particularly discloses application of an exosome overexpressing CAP and LGR5 genes in preparation of a drug for treating cartilage inflammation. The exosome overexpressing the CAP and LGR5 genes has both targeting property and cartilage protection function, the exosome can be more phagocytosed by cartilage cells, is targeted to the cartilage cells, can improve the levels of a cartilage generation gene Col2a1 and a cartilage development regulating gene Sox9, can reduce the level of a cartilage degradation gene Mmp13, can relieve cartilage abrasion of osteoarthritis mice, and can protect knee joints, so that the exosome can promote cartilage generation, relieve cartilage aging and reduce cartilage degradation under a complex inflammation environment. Further, the application provides a mesenchymal stem cell exosome overexpressing CAP / LGR5, provides a new technical scheme for targeted treatment based on stem cell engineering, and has a wide application prospect.

Nucleic acid molecules configured to specifically express a sequence of interest in a cancer cell, comprising: a transcription factor binding region comprising 3-10 repeats of a transcription factor binding site, a minimal promoter and the sequence of interest operatively linked to the transcription factor binding region and minimal promoter, wherein the transcription factor is selected from SOX9, GATA10, TCF7L1, LEF1, MYBL2 and MYB are provided. Nucleic acid molecule systems and compositions comprising the nucleic acid molecules are also provided as are methods of treating cancer.